KALY logo
Kali, Inc.(KALY)
Closing price · checked 10:43 PM ETAbout this dataData status
$0.00▲0.00 (0.00%)
Extended:$0.00-0.00 (-99.00%)· 10:43 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Kali, Inc. specializes in developing and manufacturing specialty pharmaceuticals, particularly focusing on niche markets such as pain management and oncology. The company's competitive position is bolstered by its proprietary formulations and a strategic focus on underserved therapeutic areas, primarily in the United States.

HealthcareDrug Manufacturers - Specialty & Genericlow - The company has high fixed costs associated with R&D and regulatory compliance, which limits its ability to scale efficiently.

Business Overview

01Specialty pharmaceuticals - 70%
02Generic drugs - 30%

Kali, Inc. generates revenue through the sale of specialty and generic pharmaceuticals, leveraging its proprietary formulations to command higher pricing power in niche markets. The company benefits from a streamlined production process that reduces costs and enhances margins despite current negative operating performance.

What Moves the Stock

FDA approval of new drug formulations

Market share changes in specialty pharmaceuticals

Partnerships or licensing agreements with larger pharmaceutical companies

Changes in reimbursement policies affecting drug pricing

Watch on Earnings
Gross margin percentageNet income growth rateOperating cash flow

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption in drug development

Increased competition from generic drug manufacturers

Emerging biotech firms with innovative therapies

Negative operating cash flow impacting liquidity

Potential future debt obligations if financing is required for R&D

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The healthcare sector is generally resilient, but specialty pharmaceuticals can be sensitive to changes in consumer spending and healthcare budgets.

Interest Rates

Interest rates affect Kali's financing costs for R&D and operational expansion, potentially impacting profitability and valuation multiples.

Credit

minimal - The company currently has a negative debt/equity ratio, indicating no reliance on external credit.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Investors looking for potential upside from new drug approvals and market expansion.

high - The stock has shown significant price volatility, with a recent 100% return over multiple periods.

Key Metrics to Watch
FDA approval timelines
Market share in specialty pharmaceuticals
Gross margin trends
Operating cash flow performance
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.